Navigate the critical balance of M&A, affordability, and alternative funding pathways shaping our global healthcare’s future Imagine a global chess match, where each move determines the trajectory of our healthcare system. On the chessboard are large pharmaceutical organizations, considered the vanguards of medical innovation, and the Federal Trade Commission (FTC). Their moves shape the intricate dynamics of the industry. The game’s strategic context centers on the decision-making strategies of large pharmaceutical companies, underpinned by a looming presence: antitrust regulations. Amidst this magnificent game, Pfizer’s Chief Development Officer, William Pao, articulates his concerns. Pao warns that stricter regulations may dampen the crucial M&A-dependent funding…...
Join Now